Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARG | P37231 | 14/20 | 0.59 |
| ▸ | PPARA | Q07869 | 14/20 | 0.59 |
| ▸ | MAPT | P10636 | 3/20 | 0.51 |
| ▸ | TP53 | P04637 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 6/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 6/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5448777 | 0.94 | PPARG (0.58) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5434590 | 0.92 | PPARG (0.57) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5226570 | 0.92 | PPARG (0.63) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5437419 | 0.87 | PPARG (0.55) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5262261 | 0.86 | PPARG (0.62) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5439211 | 0.84 | PPARG (0.61) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5224911 | 0.80 | PPARG (0.56) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5262477 | 0.80 | PPARG (0.57) | PPARGPPARAMAPTTP53CYP2C9 | |
| SCHEMBL5259696 | 0.79 | PPARG (0.59) | PPARGPPARACYP2C9KCNH2 | |
| SCHEMBL5224923 | 0.79 | PPARG (0.61) | PPARGPPARACYP2C9KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | CRYSTAL GENOMICS, INC. (KR) | 2007-11-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070254882-A1 | Sulfamide Derivatives and Pharmaceutical Composition for Upregulation of Lipid Metabolism Comprising Same | SULT2A1, SPTLC2, SGMS2 | PPARG 399/4885PPARA 190/4885MAPT 3705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.